|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.67 USD | -1.61% |
|
-11.14% | +121.08% |
| 05-07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
| 05-06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
ADC Therapeutics SA announced that Chris Martin, DPhil, has stepped down as chief executive officer. The company announced that Ameet Mallik has been appointed as its new chief executive officer. He will be based from the company's office in New Providence, New Jersey.
Ameet Mallik's pharmaceutical career was highlighted by 16 years at Novartis, most recently as Executive Vice President and Head of U.S. Oncology.
| 1st Jan change | Capi. | |
|---|---|---|
| +121.08% | 353M | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.67% | 21.97B | |
| -4.64% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
ADC THERAPEUTICS SA 
